Boehringer Ingelheim builds Digital Lab "BI X" with focus on innovative digital solutions in healthcare

Boehringer IngelheimWith the founding of BI X as independent subsidiary Boehringer Ingelheim will focus on breakthrough innovative digital solutions in healthcare from idea to pilot. The start-up will work closely together with all three business units of the company - Human Pharma, Animal Health and Biopharmaceuticals. It will provide a platform for collaborating with specialists in the field of data science, agile software development and user experience design.

"The future employees of BI X will tackle challenging tasks, collaborate with experts from many different disciplines to deliver meaningful solutions for Boehringer Ingelheim and its customers," outlines Michael Schmelmer, CIO of Boehringer Ingelheim and head of the digital lab.

BI X will develop prototypes for new products and solutions and test them together with the company's business units in pilot phases. The business units will then use the successfully developed new products and solutions themselves and bring them to the market. This approach is to ensure that knowledge and experience accrued at BI X are being quickly integrated into the digital lab's parent house.

Emphasizing the importance to the company, Simone Menne, member of the Board of Managing Directors of Boehringer Ingelheim, responsible for the Corporate Board Division Finance and sponsor of BI X says: "Digitalization is a strategic topic for our company and will enable us to provide even better treatment options for patients in the future. We are driving the digital transformation with many different initiatives in all business areas - BI X will further accelerate this change process. It will help us to ride the wave of digitization and to become a leader in digital healthcare. Being a separate legal entity from the parent house, BI X combines the freedom of a start-up with the power of one of the world’s leading pharma companies."

BI X will serve as a digital lab for its parent house, taking up operations in July 2017. Boehringer Ingelheim is set to invest 10 million euros in BI X in 2017 and has started to recruit globally a multidiscipline team of 50 specialists. The digital lab will be located in Ingelheim at the company's headquarters in Germany.

For further information, please visit:
http://www.bix-digital.com

About Boehringer Ingelheim
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.

Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...